SYGNIS To Host Live Webinar On Its Revolutionary Sunscript RT Technology For Reliable And Robust RNA Amplification
• Live webinar to be held by CSIC Research Professor Luis Menéndez-Arias, a renowned expert in human immunodeficiency virus reverse transcriptase
• SunScript(TM) reverse transcriptase provides significant advantages including improved thermostability, efficiency and synthesis of long transcripts
Madrid, Spain and Heidelberg, Germany, October 14 th , 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will host a live webinar entitled 'SunScript(TM) Reverse Transcriptase: Reliable and Robust RNA amplification at high temperatures' on Wednesday, October 21, starting at 5:00 PM CET (11:00 AM EDT).
The complimentary webinar will be hold by Prof. Luis Menéndez-Arias from the CSIC (Consejo Superior de Investigaciones Científicas), the Spanish National Research Council and biggest public institution dedicated to research in Spain and the third largest in Europe. Prof. Menéndez-Arias is an internationally recognized expert in human immunodeficiency virus (HIV) reverse transcriptase and is currently working as Research Professor at the Spanish Centro de Biología Molecular 'Severo Ochoa' in Madrid.
'I am very happy to get the opportunity to talk about a product that really can help researchers in molecular biology to significantly improve workflows and results,' Prof. Menéndez-Arias commented. 'Researchers working in gene expression profiling or diagnostics often need to study RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR). The ability to transcribe and amplify genomic information in just one step could make SunScript(TM) Reverse Transcriptase an indispensable tool in human genetics, personalized medicine, oncology and molecular diagnostics.'
SYGNIS' SunScript(TM) product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) derived from the well characterized human immunodeficiency virus (HIV-1) and which today is one of the most thermostable and efficient enzymes commercially available.
SYGNIS host this webinar as part of its extensive promotional program to promote and commercialize SunScript(TM) in the corresponding markets. The Company plans a wide range of additional marketing events around its product portfolio including mailing campaigns and presentations at key international scientific meetings and conferences.
For more information and to register for the webinar, visit www.sygnis.com/email/webinar21oct2015/index.html. The event will also be recorded and available for on-demand viewing at www.sygnis.com.
About Prof. Luis Menéndez-Arias
Luis Menéndez-Arias is a CSIC Research Professor working at the Centro de Biología Molecular 'Severo Ochoa' (Madrid, Spain) since 1994.
He received a Ph.D. in biology from Complutense University (Madrid, Spain) and worked as a postdoctoral fellow in the Frederick Cancer Research and Development Center (Maryland, USA).
His research is devoted to studying structure-activity relationships in human immunodeficiency virus reverse transcriptase, elucidating mechanisms of resistance to antiretroviral drugs and understanding viral replication fitness.
About SunScript(TM) RT
SYGNIS' SunScript(TM) product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) for a broad range of applications in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
• SunScript(TM) reverse transcriptase provides significant advantages including improved thermostability, efficiency and synthesis of long transcripts
Madrid, Spain and Heidelberg, Germany, October 14 th , 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will host a live webinar entitled 'SunScript(TM) Reverse Transcriptase: Reliable and Robust RNA amplification at high temperatures' on Wednesday, October 21, starting at 5:00 PM CET (11:00 AM EDT).
The complimentary webinar will be hold by Prof. Luis Menéndez-Arias from the CSIC (Consejo Superior de Investigaciones Científicas), the Spanish National Research Council and biggest public institution dedicated to research in Spain and the third largest in Europe. Prof. Menéndez-Arias is an internationally recognized expert in human immunodeficiency virus (HIV) reverse transcriptase and is currently working as Research Professor at the Spanish Centro de Biología Molecular 'Severo Ochoa' in Madrid.
'I am very happy to get the opportunity to talk about a product that really can help researchers in molecular biology to significantly improve workflows and results,' Prof. Menéndez-Arias commented. 'Researchers working in gene expression profiling or diagnostics often need to study RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR). The ability to transcribe and amplify genomic information in just one step could make SunScript(TM) Reverse Transcriptase an indispensable tool in human genetics, personalized medicine, oncology and molecular diagnostics.'
SYGNIS' SunScript(TM) product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) derived from the well characterized human immunodeficiency virus (HIV-1) and which today is one of the most thermostable and efficient enzymes commercially available.
SYGNIS host this webinar as part of its extensive promotional program to promote and commercialize SunScript(TM) in the corresponding markets. The Company plans a wide range of additional marketing events around its product portfolio including mailing campaigns and presentations at key international scientific meetings and conferences.
For more information and to register for the webinar, visit www.sygnis.com/email/webinar21oct2015/index.html. The event will also be recorded and available for on-demand viewing at www.sygnis.com.
About Prof. Luis Menéndez-Arias
Luis Menéndez-Arias is a CSIC Research Professor working at the Centro de Biología Molecular 'Severo Ochoa' (Madrid, Spain) since 1994.
He received a Ph.D. in biology from Complutense University (Madrid, Spain) and worked as a postdoctoral fellow in the Frederick Cancer Research and Development Center (Maryland, USA).
His research is devoted to studying structure-activity relationships in human immunodeficiency virus reverse transcriptase, elucidating mechanisms of resistance to antiretroviral drugs and understanding viral replication fitness.
About SunScript(TM) RT
SYGNIS' SunScript(TM) product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) for a broad range of applications in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.